Continuous-time Markov processes are frequently used to describe the evolution of a disease over different phases. Such modeling can provide estimates for important parameters that are defined on the paths of the process. A simple example is the mean first hitting time to a set of states. However, more interesting events are defined by several time points such as the first time the process stays in state j for at least time units. These kinds of events are very important in relapsing-remitting diseases such as in multiple sclerosis (MS) where the focus is on a sustained worsening that lasts 6 months or longer. The current paper considers data on independent continuous Markov processes that are only observed intermittently. It reviews modeling and estimation, presents a new general concept of hitting times, and provides point and interval estimates for it. The methodology is applied to data from a phase III clinical trial of Avonex-a drug given to MS patients.
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory, slowly progressing disease of the central nervous system. Most MS patients begin their disease in a relapsing-remitting phase that is characterized by periods (usually days or weeks) of relapses during which new neurological symptoms appear, followed by periods (usually months or years) of remissions during which patients fully or partially recover. Over time, disability accumulates and many patients elapse into a more severe form of MS called "secondary progressive" that is characterized by a gradual worsening of the disease between relapses. Disability is quantified by the expanded disability status scale (EDSS) that ranges from 0 (normal neurological examination) to 10 (death due to MS) in half point steps. Despite being criticized for placing too much emphasis on walking ability, the EDSS is the most used measure of disability and disease progression in both observational and clinical studies of MS.
One challenging problem in MS studies is that of describing or predicting the course of the disease. Measures of disease progression, such as the time expected in order to arrive at a certain level of disability or graphs delineating the probability of progression as a function of time are important for both physicians and patients. However, the heterogeneity in the course of the disease makes prediction a very difficult task. Furthermore, because of the relapsing-remitting nature of the disease, neurological symptoms that appear as a result of an attack may be temporary. Therefore, many studies focus on time to sustained progression defined as an increase in the EDSS level that lasts for 6 (sometimes 3) months or longer. Thus, not only is * To whom correspondence should be addressed.
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Several authors (Albert, 1994; Mandel and others, 2007; Mandel and Betensky, 2008) have suggested Markov transition models as possible initial models for estimating measures of MS progression. Such models may approximate reasonably well the real biological process when focusing on the lower range of the EDSS scale, e.g. defining progression as reaching an EDSS of 3. However, while the above mentioned studies consider processes in a discrete-time framework, the real underlying process evolves continuously in time. For example, a typical MS study measures the EDSS of patients every 3 or 6 months, while progression may occur at any time regardless of the observation time points.
The current paper deals with inference on continuous Markov processes over a discrete state space when data are collected at known and fixed time points. The trial analyzed in Section 4 is an example in which data were collected on MS patients every 6 months, but the transition between levels of the EDSS-the state space-could occur at any time. Such data are called panel data. Lawless (1985, 1989) discuss inference under the Markov assumption and provide methods for estimating basic properties of the process such as its stationary distribution and the mean sojourn time in a state. Gentleman and others (1994) derive the distribution of the first hitting time to a state, called also the first passage time, and discuss the importance of this functional in the context of AIDS. Here, we focus on estimation of a new general concept of a hitting time that is defined as the first time of reaching a state and staying there for at least time units. As described above, this corresponds to the time to sustained progression in MS. We derive expressions for the mean and for the distribution of time to sustained progression and provide estimators based on panel data. The estimators are relatively simple, though for some purposes intensive computation is required.
PROBABILISTIC PROPERTIES

Hitting times
Let (X t ) t 0 be a continuous, irreducible Markov process with parameter (a, Q) and state space {1, 2, . . . , J }, where a is a column vector of initial probabilities a = (P(X 0 = i)) and Q is the intensity matrix with elements q i j 0 for i = j and q ii = − j =i q i j ≡ −q i . We denote by a j the indicator vector of state j, that is, a vector all of whose elements are zero except the jth element which is 1. This vector replaces a when the analysis is conditional on the initial state X 0 and X 0 = j.
Let Z = inf{t : X t = J } denote the time the process first hits state J , and letQ be as Q but with the J th row replaced with zeros, i.e. J becomes an absorbing state. Properties of Z have been intensively studied under the general term phase-type distributions (see Neuts, 1981 , for a review). The distribution of Z is given by
where F R denotes the distribution function of a random variable R. Note that Z is a continuous random variable with a possible atom at 0 having probability a a J = P(X 0 = J ).
The distribution (2.1) is obtained by arguments similar to those used for discrete models, as described in Section 2.3. However, the more standard representation of F Z involves only matrices of order J − 1 (Neuts, 1981) : LetQ be the matrix obtained by removing the J th row and the J th column of Q, and let Q J be a vector containing the first J − 1 elements of the J th column of Q. Similarly, letǎ be a vector containing the first J − 1 elements of a. Using the fact that Q J = −Q1 J −1 , where 1 j is a vector of ones of length j, it can be shown that
By defining the state J in an appropriate way, the distribution of Z can be used to describe progression of many diseases (e.g. Gentleman and others, 1994) . However, for relapsing-remitting diseases such as MS, and for general not progressive Markov processes, reaching a state is not an indication of progression, at least not the most interesting one. For example, the outcome of most MS studies is sustained progression defined by a worsening that lasts more than 6 months (e.g. Jacobs and others, 1996; Gauthier and others, 2007) . We thus let denote a time period of interest (e.g. 6 months) and consider the indicator process A J (t) = I {X s = J ; t s < t + }, (t 0), of being in J during the whole time period [t, t + ). Our main aim is to study properties of the distribution of Y = inf{t : A J (t) = 1}, the time until the first visit to J with a sojourn time greater than . The analysis is more complicated than that of the classical hitting time Z because it must take into account paths that go through J several times with sojourn times less than .
We will use the following additional notation: S 1 , S 2 , . . . denote the sojourn times in state J at visits 1, 2, . . .; K = min{n : S n > } denotes the number of visits to J until first staying there more than time units; and R 1 , R 2 , . . . are the returning times to J (sojourn times out of J ) after visits 1, 2, . . . to state J .
The following are direct results of the Markov assumption:
where p J is the vector of transition probabilities from state J :
.
Our main interest concerns the law of Y that, as mentioned above, represents time until sustained progression in MS. This can be obtained by first calculating the joint law of Y and K and then summing over K . We have
and by conditioning on Z and S 1 , 5) for k = 2, 3, . . ., where P a,Q denotes the probability under a Markov process with parameter (a, Q). These equations express the joint law as a recursion in k. When a assigns no mass to J , then a a J = 0 and the second term in (2.5) is cancelled. The recursion formula requires successive numerical integrations and involves an infinite sum. An alternative more attractive way for calculating properties of F Y is by using the following representation of Y : where, by the strong Markov property (Norris, 1997) , Z , S 1 , S 2 , . . . , R 1 , R 2 , . . . are independent. Since K = min{n : S n > } depends only on the sojourn times in J , R 1 , . . . , R k−1 |K = k are independent having the law (2.2). Moreover, by independence of S 1 , S 2 , . . . it follows that S 1 , . . . , S K −1 |K = k are independent random variables all having the distribution (2.3).
Frequently, interest lies in the time to hitting a set of states, S, rather than the time to a single state. A representation similar to (2.6) still holds if there exist states j ∈ S andj ∈S such that the transition from S toS is always through j and the transition fromS to S is always throughj. The birth and death model is the most important process of this type and the one used in the sequel. Under such models, R i is calculated as in (2.2) above with all states in S replaced with one absorbing state in an obvious way and, similarly, S i is calculated with all states inS replaced with an absorbing state.
Mean hitting times
Let μ J i be the mean hitting time to state J starting from state i (i.e. the expectation of Z under (a i , Q)), and let
The results above give:
. . are independent of K , and E(S K ) = +q −1 J from the memorylessness property of the exponential distribution and the fact that P(S K t) = P(S 1 t|S 1 > ). Putting all terms together and rearranging them, we arrive at
Discrete models
In discrete Markov models, the transition matrix P = P(θ ) determines the evolution of the process. Calculations of time-to-event quantities are carried out by specifying a coupled Markov process that enters an absorbing state when the event of interest occurs. Probabilities of the original process are then equivalent to probabilities of being in the absorbing state of the coupled process (Mandel and others, 2007) and can be readily obtained from the powers of its transition matrix. As a concrete example, consider the time to sustained progression defined as the first 2 consecutive visits in states larger than the initial state, which is a popular end point in MS studies. If P = ( p i j ) is a 3 × 3 transition matrix, then the probability of sustained progression starting from states 1 and 2 is calculated by taking powers of the matrices of the coupled processes with transition matrices For calculating the mean time to a state, letP(θ) be a J × J transition matrix of a Markov process whose first J − 1 states are transient and whose J th state is absorbing. Denote by k i (θ) the mean hitting time to J starting in state i, and letP −J (θ) be the (J − 1) × (J − 1) submatrix ofP(θ ) obtained by omitting the J th row and the J th column fromP(θ ). The mean times
If a is a vector of initial probabilities, then the unconditional mean time to J is simply a K (θ ).
Simple modifications of P enable calculation of the mean and the distribution function of various timeto-event variables. Albert (1994) suggests estimators for the mean hitting time to a set of states using quite complicated recursion formulas. The approach suggested here considerably simplifies the calculation of estimators and their asymptotic standard errors (SEs; see Section 4 for more details).
ESTIMATION
Panel data usually do not contain either X 0 or the time the process started (e.g. the onset of the disease) but only the time elapsed between successive observations. If data on X 0 are available, a can be estimated by the empirical distribution of the initial state. When interest lies on time-to-event probabilities conditionally on the current state, information on a is irrelevant. We therefore focus on estimation of Q.
Estimation of Q
Consider panel data on N independent patients. Let t 0i , . . . , t n i i and y 0i , . . . , y n i i be the observation times and the corresponding states occupied by subject i and assume that the observation times are fixed. The likelihood, conditionally on the initial state, is given by
where w ji = t ji − t j−1i and p k, (w; θ) is the (k, ) entry of the transition matrix P(w, θ) = e w Q(θ) (Norris, 1997) . The matrix Q may depend on a covariate vector x so that Q = Q(θ, x).
The maximum likelihood estimate is therefore obtained by solving S(θ) = 0, where S is the score vector with uth element
Kalbfleisch and Lawless (1985) develop a scoring algorithm for solving the estimating equations above using the relations between the eigenvectors and eigenvalues of P(w, θ) and Q(θ). The R package Panel (Gentleman, 2006) can be used to obtain the maximum likelihood estimator of γ = log(θ ) and an estimate of its variance matrix. Other variants for obtaining estimates can be found in Cook and others (2002) and Chao (1995, 1996) .
Estimating time to progression
Once estimates for Q are obtained, estimates for time-to-event quantities such as E(Y ) and F Y (t) can be calculated by plugging the estimate of Q into (2.4), (2.5), and (2.7). The variance can be estimated by the delta method.
This direct approach is easy to implement for E(Y ) but is rather complicated for F Y . Instead, we suggest to estimate F Y using a simulation approach that makes use of (2.6) and the independence properties discussed below (2.6). Thus, we can generate independent realizations of Y as follows.
1. Generate K from the Geo(e −q J ) distribution and independently generate Z from (2.1). 2. Given the value of K in 1, generate R 1 , . . . , R K −1 independently from the distribution (2.2) and generate S * 1 , . . . ,
The variables Z and R 1 , . . . , R K −1 can themselves be generated by simulating Markov processes. However, a much more efficient approach is to estimate the distributions (2.1) and (2.2) on a fine grid and then to generate Z and R i by the inversion formula of a uniform random variable, e.g. To calculate the variance ofF Y (y), we suggest to use the simulation method of Mandel and others (2007) that approximates the distribution ofθ by the N (θ ,V (θ )) distribution, whereV (θ ) is an estimate for Var(θ) obtained from the scoring algorithm discussed above:
3. Calculate the sample variance of (F θ 1 (y), . . . ,F θ L (y)).
Estimation of the variance requires generating L random samples of Y , each of size B.
APPLICATION TO MS PROGRESSION
Data
The data analyzed here include 68 treated and 72 untreated MS patients who participated in a phase III clinical trial that evaluated the drug Avonex for relapsing-remitting MS patients. This is a subsample of the original study of patients who enrolled early to the trial and completed 3 magnetic resonance imaging scans (Rudick and others, 1999) . The patients selected are in the early stage of their disease with a relatively low EDSS (eligible to the study were patients with EDSS smaller than 3.5 at enrollment). Here, we define the states as: 1, no disability (EDSS 1.5); 2, minimal disability (EDSS = 2, 2.5); and 3, moderate or severe disability (EDSS 3). We estimate the mean and the distribution of the time to moderate or severe disability (state 3) for patients having no disability (state 1). We primarily focus on the time to sustained progression, defined as a period of 6 months or longer in state 3.
Patients' visits were scheduled every 6 months (26 weeks) but actual visits varied. The left panel of Figure 1 presents the distribution of actual gaps between successive visits for the untreated arm. Among the 531 transitions, only 86 are at exactly 26 weeks; and 71 and 38 transitions deviate from the schedule by 1 and 2 weeks, respectively. The other gaps between visits are spread out from 1 to 45 weeks. The first step in the analysis is, therefore, to examine the assumption that unscheduled visits are independent of the disability process. This is graphically tested against the alternative that unscheduled visits are due to worsening or improvement of the disease. The line in the right panel of Figure 1 displays the expected number of transitions that show worsening or improvement under the assumption of independence of the gap between visits and the EDSS. The circles show the respective observed numbers. If unscheduled visits (i.e. short gaps between successive visits) are attributed to change in the EDSS, we will see more than expected transitions there. The figure indicates that this is indeed the case. The result of a parametric bootstrap test (Davison and Hinkley, 1997) , using the chi-square statistic, supports this finding (P-value 0.001). We therefore include only scheduled visits defined as those that occur within a 4-week discrepancy of the 6-month period predefined by the study. Table 1 summarizes the transitions for the different gaps between visits, which is the sufficient statistic for the model.
Model
The following birth and death model is considered
The model assumes continuity of the disability process in time so that a period (though arbitrarily short) of a disability level of 2 must precede a disability level of 3. This is a very reasonable model for MS and for many other diseases where "jumps" in the underlying process are excluded. Besides the biological plausibility of the birth and death model, the use of a tridiagonal matrix has also a theoretical advantage: the eigenvalues of such matrices are all real (when the off-diagonal elements are of the same sign) and this guarantees the identifiability of Q. We tested the equivalence of Q trt and Q untrt , the intensity matrices of the treated and untreated arms and found no significant difference (likelihood ratio test with 4 df: P-value = 0.125). Still, we analyzed the data separately for the 2 arms as the original study that was based on more data did find a significant difference (Jacobs and others, 1996) .
As Kalbfleisch and Lawless (1985) commented, it is common to find that time-homogeneous Markov models are not strictly appropriate. Fitting Markov models is, nonetheless, a useful and often necessary first step in developing a suitable model. The time-homogeneous Markov model is a convenient baseline; insight can be obtained by examining the nature of departures from this model. In this spirit, goodness-of-fit tests for the Markov assumption can be conducted by embedding the model in a larger model and using the likelihood ratio test. A natural direction to test against is an inhomogeneous alternative. We therefore considered an inhomogeneous model in which transitions during the first 5 years of the disease differ from those at later stages. We obtained P-values of 0.25 and 0.79 for the treated and untreated arms, respectively (likelihood ratio test with 4 df). We further examined the dependency of the Q matrix on individuals' characteristics. Previous studies showed that brain parenchymal fraction (BPF), which measures tissue loss in the brain, is highly associated with the EDSS level. We tested for different Q matrices for patients with high and low baseline BPF (cutoff 0.83, the median of the treated arm) and obtained P-values of 0.23 and 0.47. Although the tests could not reject the homogeneous Markov model, this may well be because of the small sample size, and the homogeneous Markov model should be interpreted as a crude approximation to reality.
Estimates of transition rates
Assuming all visits were as scheduled (26 weeks), the 6-month transition matrices, P untrt = e Q untrt and P trt = e Q trt , were naively estimated by direct enumeration of each transition type (we use 6-month time units so that P ≡ P(1) contains the 6-month transition probabilities). This gives the matrices Of note is the relative low probability of the transitions 1→3 and 3→1, with the former being higher. This reflects the slow progression rate of MS and the relapsing-remitting nature of the disease. Also of note is the good performance of the initial value P 0 , especially for the untreated arm. This is probably due to observation times being nearly equally spaced and to transition rates being low.
Estimating mean hitting times
The mean hitting time to state 3 and the mean time to hitting state 3 and staying there for at least 6 months are measures of disease progression that can be easily interpreted and compared. The latter quantity is important because it corresponds to the mean time to sustained progression, an outcome used in many clinical and observational studies of MS. Estimates are derived as described in Section 2.2 using = 1 and the estimatesQ untrt andQ trt given above. The mean hitting time to state 3 for the model (4.1) is
Using the results of Section 4.2, the mean hitting times and SEs for patients who start in state 1 are estimated to be 4.8 (SE = 0.8) and 7.4 (SE = 1.4) for the placebo and Avonex arms, respectively. Recalling that the time units are of 6 months, we conclude that Avonex lengthens the time from no disability to moderate disability on average by more than 1 year. It is now known that Avonex is effective in reducing the relapse rate, and hence it postpones short-term progression. The mean time to sustained progression (time to staying more than 6 months in state 3) is more interesting and, by (2.7), is given by
It depends on the initial state only through the mean time of Z . The estimates of the mean time to sustained progression starting in state 1 are 5.7 (SE = 0.9) and 9.4 (SE = 1.7) for the placebo and Avonex arms, respectively. Thus, the mean time for a patient who currently has no disability (state 1) to progress to sustained moderate disability (state 3) is estimated to be a little less than 3 years without any treatment and increases to 4.5 years for patients treated with Avonex. Thus, on average, Avonex lengthens the time to moderate disability by a year and a half. It is interesting to compare the analysis above to that of a discrete Markov model. The mean hitting times under a discrete model are calculated as described in Section 2.3. Here, we take θ = ( p 11 , p 12 , p 21 , p 22 , p 31 , p 32 ) and estimate the mean hitting time to state 3 and the mean time to hitting state 3 and staying Estimating disease progression using panel data 313 there at least 2 consecutive visits (sustained progression) using 
respectively. The time of sustained progression in the discrete model is defined to be the second visit to state 3, that is, 6 months after reaching the state. In order to compare the results to these obtained in the continuous model, we subtracted 1 (6 months) from (2.8).
To estimate the SEs of the mean hitting times, K (θ ), the derivatives with respect to the parameters θ are needed. Let P be a transition matrix of order J × J as defined in Section 2.3, then
In the model considered here, θ = ( p i j ) and the derivative reduces to [,i] is the ith column of a matrix A and K j is the jth element of K .
Under the discrete model, the estimates of the mean time to state 3 starting in state 1 are 5.8 (SE = 0.8) and 9.6 (SE = 1.7) for the placebo and Avonex arms, respectively. The respective estimates of the mean time to sustained progression are 6.8 (SE = 1.3) and 12.0 (SE = 2.9). These estimates are larger than the ones obtained under the continuous model by 1-2 time units which correspond to a longer mean time of about 6-12 months.
Distribution of time to progression
Using the estimated Q matrix, we calculated the distribution of time to sustained progression using the simulation method described in Section 3.2. In order to generate copies of Z and R, we first calculated their distributions on a grid with increments of 0.01 and then used the inversion method of a uniform (0, 1) random variable. Following the steps described in Section 3.2, we simulated a total of B = 50 000 copies of Y , the time to sustained progression, and estimated its distribution by the empirical distribution function. We then calculated a pointwise 95% level confidence interval using the simulation approach described at the end of Section 3.2 with L = 1000. Figure 2 depicts the estimates of the distribution of time to sustained progression (having a moderate disability for more than 6 months) starting in state 1 (no disability). The figure provides a more complete summary of the utility of Avonex than the mean hitting time discussed previously. It reveals, for example, that after 2 years the probability of sustained progression in the Avonex group is 0.31, while without treatment it is as high as 0.46; thus, Avonex reduces the 2-year probability of sustained progression by 33%. However, the confidence intervals are quite wide as a result of small sample sizes, so that the real effect may be smaller.
The figure also compares the estimates under the continuous and the discrete models, the latter being simpler but less plausible. The 2 models predict similar progression curves for the placebo arm but do not agree well in the Avonex arm. The discrete model predicts slower progression rates under both arms, which is consistent with the results of the mean hitting times.
Simulation
The performance of the method and its sensitivity to model misspecification were evaluated using simulation. The study considered data similar to ours (60 subjects with 5 transitions) and its main results are reported below. The supplementary material available at Biostatistics online contains a detailed description of the study plan and the tables of results.
When the Markov assumption holds, the bias of the estimator is small and the confidence intervals are only moderately conservative or liberal (Table 1 of the supplementary material available at Biostatistics online). The results of the sensitivity study show that when omitting a covariate, the bias is quite small, but the confidence intervals are anticonservative (Table 2 of the supplementary material available at Biostatistics online). When the true intensity matrix is time-dependent, the bias is not negligible, but the confidence intervals are only slightly anticonservative (Table 3 of the supplementary material available at Biostatistics online). The performance of the method is poor when the true process is semi-Markov with sojourn times that are not exponentially distributed (Table 4 of the supplementary material available at Biostatistics online).
DISCUSSION
We study a general form of hitting times under a continuous Markov model and discuss and demonstrate estimation of Q from panel data. Hitting times can be of interest also when data on transitions and sojourn times are available as in multistate analysis (e.g. Hougaard, 2000) . Estimation of quantities as discussed here follows the same lines after obtaining estimates for Q and for its variance.
Our method of estimating the distribution function is essentially a Monte Carlo algorithm. An alternative approach is to simulate many realizations of whole processes based on the estimated parameters until the event of interest occurs. The method presented here is much more efficient since it does not require simulation of transitions between the transient states-a task that can be quite intensive in certain models. It also provides some insight into the model and an expression for the mean hitting times both of which are of interest in their own right.
The assumption of fixed observation times can be relaxed to some extent by assuming random observation times that are independent of the Markov process. However, frequently, observation times are related to changes in the process, as is probably the case in our data, and methods for exploiting such data are necessary. The phenomenon is similar to, but not exactly the same as, missing not at random. The Markov assumption provides an explicit relation between the matrices Q and P(t), hence making calculation and estimation feasible. However, as aforementioned, time-homogeneous Markov models are not always appropriate. Only few papers that deal with panel data try to relax the Markov assumption. Cook and others (2002) enable different absorbing states for different subjects. Kang and Lagakos (2007) fit panel data to a semi-Markov process assuming that sojourn times are either exponential distributed or bounded below by a known constant. Other extensions of the Markov model and methods for obtaining derived quantities are needed.
SUPPLEMENTARY MATERIAL
Supplementary material is available at http://biostatistics.oxfordjournals.org.
